Hims&Hers Health trims workforce amid strategic realignment
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/31/2026
- Wall Street ends higher as Amazon soothes AI jitters
- Amazon shares rally as cloud growth surges and spending outlook climbs
- Apple shares sink on disappointing September quarter sales outlook
- Novo Nordisk stock tumbles 10% as key trial misses goal
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- KBR names its Mission Technology Solutions spinoff Trinzic
- Wall Street ends sharply higher, lifted by soaring Microsoft
- SCYNEXIS (SCYX) Move Attributed to Morning Note from Brookline
- AbbVie (ABBV) Misses Q2 EPS by 6c, Beats on Revenue; Offers FY26 EPS Guidance
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
TD Cowen on Hims and Hers (HIMS): 'acquisition of ZAVA reflects its commitment to expand into international markets'
June 3, 2025 12:08 PM EDTTD Cowen analyst Jonna Kim reiterated a Hold rating and $38.00 price target on Hims and Hers (NYSE: HIMS).
The analyst comments "HIMS' acquisition of ZAVA reflects its commitment to expand into international markets and we think this was largely expected by the market... More
Hims & Hers Health, Inc. (HIMS) Rapidly Selling $6 to a 60 Handle, Remains +675bps on Day
June 3, 2025 10:03 AM EDTHims & Hers Health, Inc. (NYSE: HIMS) Rapidly Selling $6, Remains +675bps on Day
... MoreTruist on Hims and Hers (HIMS): 'likely has the opportunity to up-sell', 'we believe HIMS is likely to still have financial capacity to announce additional deals'
June 3, 2025 10:01 AM EDTTruist Securities analyst Jailendra Singh reiterated a Hold rating and $45.00 price target on Hims and Hers (NYSE: HIMS).
The analyst comments "Bottom Line. Considering HIMS already saw early traction in the UK, the company's recent DTC telehealth acquisition in the region is an unsurprising next step to... More
Citi Reiterates Sell Rating on Hims and Hers (HIMS), PT $30
June 3, 2025 9:20 AM EDTCiti analyst Daniel Grosslight reiterated a Sell rating and $30.00 price target on Hims and Hers (NYSE: HIMS).
The analyst comments "This morning, HIMS announced it is acquiring ZAVA, a digital health platform with operations in France, the UK, Germany, and Ireland (LINK). The... More
Leerink Partners on Hims and Hers (HIMS): 'we do see some execution and integration risk associated with the deal'
June 3, 2025 8:56 AM EDTLeerink Partners analyst Michael Cherny reiterated a Market Perform rating and $42.00 price target on Hims and Hers (NYSE: HIMS).
The analyst comments "Bottom Line: HIMS' acquisition of ZAVA (private) for an undisclosed price marks a significant strategic expansion for the company as it materially increases its international footprint. On paper, the tieup makes sense. ZAVA offers the same products... More
BofA Securities Reiterates Underperform Rating on Hims and Hers (HIMS), 'Core growth in US slowing notably'
June 3, 2025 8:06 AM EDTBofA Securities analyst Michael Cherny reiterated an Underperform rating and $28.00 price target on Hims and Hers (NYSE: HIMS).
The analyst comments "Bloomberg Second Measure (BSM) data indicates total orders are growing just 3-4% y/y in 2Q through mid-May, significantly below 8% in... More
